NICE rejects Afinitor (Novartis) for HER-2 negative, hormone receptor-positive Breast Cancer
NICE(The National Institute of Health and Clinical Excellence)in a provisional draft guidance has rejected Afinitor ((everolimus) from Novartis, for the treatment of HER-2 negative, hormone receptor-positive Breast Cancer. Patients with this condition have an average of 18-36 months to live from diagnosis and Afinitor is the first treatment offering a positive effect on the condition that affects 30,000 women in the UK. Aromasose inhibitors are the prime therapy but resistance develops to these compounds.
NICE was not impressed with the overall survival data from Afinitor and therefore did not see it as a cost effective treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.